Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Research &;; Experimental (6)
- Research & Experimental (3)
- Biochemistry & Molecular Biology;; Cell Biology;; Medicine (2)
- General & Internal (2)
- A-BETA;; MICROGLIAL ACTIVATION;; ENDOCANNABINOID SYSTEM;; TGCRND8 MICE;; TANGLES;; PROTEIN;; CANNABINOIDS;; INFLAMMATION;; BRAIN;; NEUROINFLAMMATION;; Biochemistry & Molecular Biology;; Cell Biology;; Medicine (1)
-
- AGGRESSIVE YOUTH TRAAY;; TREATMENT RECOMMENDATIONS;; TRENDS;; Pediatrics;; Pharmacology & Pharmacy;; Psychiatry (1)
- ATTENTION-DEFICIT/HYPERACTIVITY DISORDER;; DEFICIT HYPERACTIVITY;; DISORDER;; PREFRONTAL CORTEX;; D1 GENE;; ASSOCIATION;; CHILDHOOD;; CHILDREN;; LINKAGE;; BRAIN;; DRD1;; Psychology (1)
- Actin;; Endothelial cells;; Inflammation;; Tissue injury;; Vitamin D binding;; protein;; FULMINANT HEPATIC-NECROSIS;; ACUTE LIVER-FAILURE;; ORGAN DYSFUNCTION;; SCAVENGER SYSTEM;; GLOBULIN;; RECRUITMENT;; CHEMOTAXIS;; TOXICITY;; INJURY;; MICE;; Immunology (1)
- Adolescence;; Diagnosis;; Premorbid;; Prodrome;; Prospective;; Psychosis;; Social adjustment;; 1ST EPISODE PSYCHOSIS;; ULTRA-HIGH-RISK;; PREMORBID ADJUSTMENT;; SCHIZOAFFECTIVE DISORDER;; NEGATIVE SYMPTOMS;; ADULT SCHIZOPHRENIA;; PRODROMAL SYMPTOMS;; BIPOLAR DISORDER;; OBSTETRIC COMPLICATIONS;; INTERRATER RELIABILITY;; Psychiatry (1)
- Adolescents;; Adverse effects;; Antipsychotics;; Children;; Pharmacovigilance;; Registry (1)
- Adolescents;; antipsychotics;; attention deficit-hyperactivity disorder;; children;; combination;; disruptive behaviour disorders;; paediatric;; polypharmacy;; 2ND-GENERATION ANTIPSYCHOTICS;; PSYCHOTROPIC MEDICATION;; ATYPICAL;; ANTIPSYCHOTICS;; PSYCHIATRIC-PATIENTS;; TARDIVE-DYSKINESIA;; CLINICAL-PRACTICE;; NATIONAL TRENDS;; ADVERSE EVENTS;; SCHIZOPHRENIA;; PATTERNS (1)
- Adult;; Antirheumatic Agents/adverse effects/ therapeutic use;; Cyclophosphamide/adverse effects/ therapeutic use;; Dose-Response Relationship (1)
- Aging;; cognition;; development;; diffusion tensor imaging;; executive;; functioning;; white matter;; CINGULATE CORTEX;; CORPUS-CALLOSUM;; LIFE-SPAN;; DIFFUSION;; BRAIN;; INTEGRITY;; ADOLESCENTS;; UNCERTAINTY;; CHOICE;; Neurosciences;; Psychiatry (1)
- All-cause discontinuation;; cohort study;; first-generation antipsychotics;; hospitalization;; long-acting injectable;; risperidone;; schizophrenia (1)
- Alzheimer's disease;; antipsychotics;; psychosis;; tau;; behavioral;; disturbance;; agitation;; POSITRON-EMISSION-TOMOGRAPHY;; PLACEBO-CONTROLLED-TRIAL;; CEREBROSPINAL-FLUID TAU;; BEHAVIORAL DISTURBANCES;; NEUROPSYCHIATRIC;; SYMPTOMS;; DOUBLE-BLIND;; RISK-FACTORS;; ANTIPSYCHOTIC MEDICATIONS;; NEUROFIBRILLARY TANGLES;; ATYPICAL ANTIPSYCHOTICS;; Clinical Neurology;; Psychiatry (1)
- Alzheimer's disease;; long-term potentiation;; neurodegeneration;; protein;; synthesis;; signaling;; translation;; EUKARYOTIC ELONGATION-FACTOR-2 KINASE;; ALZHEIMERS-DISEASE;; TRANSLATIONAL;; REGULATION;; MEMORY DEFICITS;; ENERGY SENSOR;; LIFE-SPAN;; PHOSPHORYLATION;; MECHANISMS;; PATHWAY;; HOMEOSTASIS;; Neurosciences (1)
- Anti-psychotic agent;; Aripiprazole once-monthly;; Hospitalization;; Long-acting injectable;; Schizophrenia (1)
- Antipsychotic;; pharmacogenetics;; polymorphism;; psychosis;; CLOZAPINE-INDUCED AGRANULOCYTOSIS;; DTNBP1 DYSBINDIN GENE;; INDUCED;; WEIGHT-GAIN;; HIGH-RISK HAPLOTYPE;; RECEPTOR GENE;; NEGATIVE SYMPTOMS;; DEFICIT SYNDROME;; 5-HT2A RECEPTOR;; ATYPICAL ANTIPSYCHOTICS;; FUNCTIONAL;; DISABILITY;; Psychiatry (1)
- Antipsychotics;; Quetiapine;; Aripiprazole;; Psychosis;; Schizophrenia;; Children;; Adolescents;; Randomised trial;; Benefits;; Harms;; SCHIZOPHRENIA-SPECTRUM DISORDERS;; EARLY-ONSET SCHIZOPHRENIA;; QUALITY-OF-LIFE;; FULLY CONDITIONAL SPECIFICATION;; PLACEBO-CONTROLLED;; TRIAL;; OPEN-LABEL;; 2ND-GENERATION ANTIPSYCHOTICS;; MULTIPLE IMPUTATION;; NATIONAL TRENDS;; 1ST-EPISODE SCHIZOPHRENIA;; Psychiatry (1)
- Antipsychotics;; adherence;; depot;; long-acting injection;; meta-analysis;; relapse;; schizophrenia;; treatment discontinuation;; SCHIZOAFFECTIVE DISORDER;; FLUPHENAZINE DECANOATE;; MAINTENANCE TREATMENT;; CLINICAL-TRIAL;; TERM TREATMENT;; DOUBLE-BLIND;; OPEN-LABEL;; RISPERIDONE;; THERAPY;; OLANZAPINE;; Psychiatry (1)
- Autoantibodies;; behavior;; FDG-microPET;; N-methyl-D-aspartate receptor;; stereological neuron count;; RESONANCE-IMAGING FINDINGS;; GLUCOSE-METABOLISM;; MICE;; AUTOANTIBODIES;; ABNORMALITIES;; MECHANISMS;; BEHAVIOR;; IMMUNITY;; MEMORY;; PET;; Endocrinology & Metabolism;; Hematology;; Neurosciences (1)
- BIPOLAR-DISORDER (1)
- Biological;; Behavioral Sciences (1)
- Biomarkers;; motor skills;; robotics;; sensory motor performance;; stroke;; MODIFIED RANKIN SCALE;; ASSISTED THERAPY;; OUTCOME MEASURE;; TRIALS;; ARCHIVE;; RELIABILITY;; REHABILITATION;; QSAR;; PATIENT;; Clinical Neurology;; Peripheral Vascular Disease (1)
- Bipolar disorders;; Early recognition;; Early intervention;; Cognitive-behavioural psychotherapy;; Intervention study;; Randomised;; controlled trial;; OF-THE-LITERATURE;; ULTRA-HIGH RISK;; SPECTRUM DISORDER;; EARLY;; INTERVENTION;; RATING-SCALE;; EARLY-ONSET;; PSYCHOSIS;; THERAPY;; PREVALENCE;; PEOPLE;; Medicine (1)
- Bone morphogenetic proteins;; lung neoplasms;; cell proliferation;; cell;; survival;; RNA interference;; preclinical drug evaluation;; microRNAs;; TRANSFORMING-GROWTH-FACTOR;; PREDICT SURVIVAL;; MESSENGER-RNA;; TUMOR-GROWTH;; EXPRESSION;; MICRORNA;; ACTIVATION;; ADENOCARCINOMA;; DORSOMORPHIN;; CARCINOMAS;; Oncology (1)
- Brain development (1)
- Brain networks;; corticobasal degeneration;; differential diagnosis;; FDG;; PET;; glucose metabolism;; PROGRESSIVE SUPRANUCLEAR PALSY;; DIFFERENTIAL-DIAGNOSIS;; PARKINSONIAN-SYNDROMES;; ALZHEIMERS-DISEASE;; ACCURACY;; PATTERNS;; ATROPHY;; ONSET;; Clinical Neurology;; Neurosciences (1)
- CD4(+) T-CELLS;; DENDRITIC CELLS;; INTERLEUKIN-1 FAMILY;; SKIN;; INFLAMMATION;; DISEASE SEVERITY;; IN-VIVO;; EXPRESSION;; TOLERANCE;; IL-36;; SUPPRESSION;; Biochemistry & Molecular Biology;; Cell Biology;; Medicine (1)
- CELL;; GLOMERULONEPHRITIS;; ERYTHEMATOSUS;; INFLAMMATION;; DISEASE;; Rheumatology (1)
Articles 1 - 30 of 72
Full-Text Articles in Medicine and Health Sciences
Brain Region-Specific Alterations In The Gene Expression Of Cytokines, Immune Cell Markers And Cholinergic System Components During Peripheral Endotoxin-Induced Inflammation, H. A. Silverman, M. Dancho, A. Regnier-Golanov, M. Nasim, M. Ochani, P. S. Olofsson, M. Ahmed, E. J. Miller, S. S. Chavan, E. Golanov, C. Metz, K. J. Tracey, V. A. Pavlov
Brain Region-Specific Alterations In The Gene Expression Of Cytokines, Immune Cell Markers And Cholinergic System Components During Peripheral Endotoxin-Induced Inflammation, H. A. Silverman, M. Dancho, A. Regnier-Golanov, M. Nasim, M. Ochani, P. S. Olofsson, M. Ahmed, E. J. Miller, S. S. Chavan, E. Golanov, C. Metz, K. J. Tracey, V. A. Pavlov
Journal Articles
Inflammatory conditions characterized by excessive peripheral immune responses are associated with diverse alterations in brain function, and brain-derived neural pathways regulate peripheral inflammation. Important aspects of this bidirectional peripheral immune - brain communication, including the impact of peripheral inflammation on brain region-specific cytokine responses, and brain cholinergic signaling (which plays a role in controlling peripheral cytokine levels) remain unclear. To provide insight, we studied gene expression of cytokines, immune cell markers and brain cholinergic system components in the cortex, cerebellum, brainstem, hippocampus, hypothalamus, striatum, and thalamus in mice following an intraperitoneal lipopolysaccharide injection. Endotoxemia was accompanied by elevated serum levels …
Gene-Based Therapies In Parkinson's Disease, P. J. Allen, A. Feigin
Gene-Based Therapies In Parkinson's Disease, P. J. Allen, A. Feigin
Journal Articles
Parkinson's disease (PD) is a progressive neurological disorder characterized primarily by the degeneration of nigrostriatal dopaminergic neurons and diminution of the neurotransmitter dopamine. Though dopamine replacement therapies such as levodopa can improve the symptoms of PD, the benefits may be overshadowed by side effects and the onset of symptoms not responsive to dopaminergic treatments (e.g., autonomic symptoms, gait and balance problems, and cognitive impairment). Furthermore, no therapies have proven to slow the neurodegenerative process. Novel approaches to address these difficult problems, and others, are being sought. Over the last decade, several innovative gene therapies for PD have entered human clinical …
A Disease-Specific Metabolic Brain Network Associated With Corticobasal Degeneration, M. Niethammer, C. C. Tang, A. Feigin, P. J. Allen, L. Heinen, S. Hellwig, F. Amtage, E. Hanspal, J. P. Vonsattel, D. Eidelberg, +3 Addtional Authors
A Disease-Specific Metabolic Brain Network Associated With Corticobasal Degeneration, M. Niethammer, C. C. Tang, A. Feigin, P. J. Allen, L. Heinen, S. Hellwig, F. Amtage, E. Hanspal, J. P. Vonsattel, D. Eidelberg, +3 Addtional Authors
Journal Articles
Corticobasal degeneration is an uncommon parkinsonian variant condition that is diagnosed mainly on clinical examination. To facilitate the differential diagnosis of this disorder, we used metabolic brain imaging to characterize a specific network that can be used to discriminate corticobasal degeneration from other atypical parkinsonian syndromes. Ten non-demented patients (eight females/two males; age 73.9 +/- 5.7 years) underwent metabolic brain imaging with 18 F-fluorodeoxyglucose positron emission tomography for atypical parkinsonism. These individuals were diagnosed clinically with probable corticobasal degeneration. This diagnosis was confirmed in the three subjects who additionally underwent post-mortem examination. Ten age-matched healthy subjects (five females/five males; age …
Brain Network Markers Of Abnormal Cerebral Glucose Metabolism And Blood Flow In Parkinson's Disease, S. C. Peng, D. Eidelberg, Y. L. Ma
Brain Network Markers Of Abnormal Cerebral Glucose Metabolism And Blood Flow In Parkinson's Disease, S. C. Peng, D. Eidelberg, Y. L. Ma
Journal Articles
Neuroimaging of cerebral glucose metabolism and blood flow is ideally suited to assay widely-distributed brain circuits as a result of local molecular events and behavioral modulation in the central nervous system. With the progress in novel analytical methodology, this endeavor has succeeded in unraveling the mechanisms underlying a wide spectrum of neurodegenerative diseases. In particular, statistical brain mapping studies have made significant strides in describing the pathophysiology of Parkinson's disease (PD) and related disorders by providing signature biomarkers to determine the systemic abnormalities in brain function and evaluate disease progression, therapeutic responses, and clinical correlates in patients. In this article, …
Consistent Abnormalities In Metabolic Network Activity In Idiopathic Rapid Eye Movement Sleep Behaviour Disorder, P. Wu, H. Yu, S. C. Peng, Y. Dauvilliers, J. Wang, J. J. Ge, H. W. Zhang, D. Eidelberg, Y. L. Ma, C. T. Zuo
Consistent Abnormalities In Metabolic Network Activity In Idiopathic Rapid Eye Movement Sleep Behaviour Disorder, P. Wu, H. Yu, S. C. Peng, Y. Dauvilliers, J. Wang, J. J. Ge, H. W. Zhang, D. Eidelberg, Y. L. Ma, C. T. Zuo
Journal Articles
Rapid eye movement sleep behaviour disorder has been evaluated using Parkinson's disease-related metabolic network. It is unknown whether this disorder is itself associated with a unique metabolic network. F-18-fluorodeoxyglucose positron emission tomography was performed in 21 patients (age 65.0 +/- 5.6 years) with idiopathic rapid eye movement sleep behaviour disorder and 21 age/gender-matched healthy control subjects (age 62.5 +/- 7.5 years) to identify a disease-related pattern and examine its evolution in 21 hemi-parkinsonian patients (age 62.6 +/- 5.0 years) and 16 moderate parkinsonian patients (age 56.9 +/- 12.2 years). We identified a rapid eye movement sleep behaviour disorder-related metabolic network …
Thalamocortical Connectivity Correlates With Phenotypic Variability In Dystonia, An Vo, W. Sako, M. Niethammer, M. Carbon, S. B. Bressman, A. M. Ulug, D. Eidelberg
Thalamocortical Connectivity Correlates With Phenotypic Variability In Dystonia, An Vo, W. Sako, M. Niethammer, M. Carbon, S. B. Bressman, A. M. Ulug, D. Eidelberg
Journal Articles
Dystonia is a brain disorder characterized by abnormal involuntary movements without defining neuropathological changes. The disease is often inherited as an autosomal-dominant trait with incomplete penetrance. Individuals with dystonia, whether inherited or sporadic, exhibit striking phenotypic variability, with marked differences in the somatic distribution and severity of clinical manifestations. In the current study, we used magnetic resonance diffusion tensor imaging to identify microstructural changes associated with specific limb manifestations. Functional MRI was used to localize specific limb regions within the somatosensory cortex. Microstructural integrity was preserved when assessed in subrolandic white matter regions somatotopically related to the clinically involved limbs, …
Hospitalization Rates In Patients Switched From Oral Anti-Psychotics To Aripiprazole Once-Monthly: Final Efficacy Analysis, John Kane, C. Zhao, B. R. Johnson, R. A. Baker, A. Eramo, R. D. Mcquade, A. R. Duca, R. Sanchez, T. Peters-Strickland
Hospitalization Rates In Patients Switched From Oral Anti-Psychotics To Aripiprazole Once-Monthly: Final Efficacy Analysis, John Kane, C. Zhao, B. R. Johnson, R. A. Baker, A. Eramo, R. D. Mcquade, A. R. Duca, R. Sanchez, T. Peters-Strickland
Journal Articles
Abstract Objective: To compare hospitalization rates in patients with schizophrenia treated prospectively with aripiprazole once-monthly 400 mg (AOM 400; an extended-release injectable suspension) vs the same patients' retrospective rates with their prior oral anti-psychotic therapy. Research design and methods: Multi-center, open-label, mirror-image, naturalistic study in a community setting in North America. Patients who required a change in treatment and/or would benefit from long-acting injectable anti-psychotic therapy were treated prospectively for 6 months with AOM 400. Retrospective data on hospitalization rates were obtained. Clinical trial registration: ClinicalTrials.gov: NCT01432444. Main outcome measures: The proportion of patients with >/=1 psychiatric inpatient hospitalization with …
Long-Acting Injectable Vs Oral Antipsychotics For Relapse Prevention In Schizophrenia: A Meta-Analysis Of Randomized Trials, Taishiro Kishimoto, A. Robenzadeh, C. Leucht, S. Leucht, K. Watanabe, M. Mimura, M. Borenstein, John Kane, Christoph Correll
Long-Acting Injectable Vs Oral Antipsychotics For Relapse Prevention In Schizophrenia: A Meta-Analysis Of Randomized Trials, Taishiro Kishimoto, A. Robenzadeh, C. Leucht, S. Leucht, K. Watanabe, M. Mimura, M. Borenstein, John Kane, Christoph Correll
Journal Articles
Background: While long-acting injectable antipsychotics (LAIs) are hoped to reduce high relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged the benefits of LAIs over oral antipsychotics (OAPs). Methods: Systematic review/meta-analysis of RCTs that lasted = 6 months comparing LAIs and OAPs. Primary outcome was study-defined relapse at the longest time point; secondary outcomes included relapse at 3, 6, 12, 18, and 24 months, all-cause discontinuation, discontinuation due to adverse events, drug inefficacy (ie, relapse + discontinuation due to inefficacy), hospitalization, and nonadherence. Results: Across 21 RCTs (n = 5176), LAIs were similar to OAPs for relapse prevention at …
Cb2 Receptor Deficiency Increases Amyloid Pathology And Alters Tau Processing In A Transgenic Mouse Model Of Alzheimer's Disease, Jeremy Koppel, V. Vingtdeux, P. Marambaud, C. D'Abramo, H. Jimenez, M. Stauber, R. Friedman, P. Davies
Cb2 Receptor Deficiency Increases Amyloid Pathology And Alters Tau Processing In A Transgenic Mouse Model Of Alzheimer's Disease, Jeremy Koppel, V. Vingtdeux, P. Marambaud, C. D'Abramo, H. Jimenez, M. Stauber, R. Friedman, P. Davies
Journal Articles
The endocannabinoid CB2 receptor system has been implicated in the neuropathology of Alzheimer's disease (AD). In order to investigate the impact of the CB2 receptor system on AD pathology, a colony of mice with a deleted CB2 receptor gene, CNR2, was established on a transgenic human mutant APP background for pathological comparison with CB2 receptor-sufficient transgenic mice. J20 APP (PDGFB-APPSwInd) mice were bred over two generations with CNR2(-/-) (Cnr2(tm1Dgen)/J) mice to produce a colony of J20 CNR2(+/+) and J20 CNR2(-/-)mice. Seventeen J20 CNR2(+/+) mice (12 females, 5 males) and 16 J20 CNR2(-/-) mice (11 females, 5 males) were killed at …
Molecular Genetic Evidence For Overlap Between General Cognitive Ability And Risk For Schizophrenia: A Report From The Cognitive Genomics Consortium (Cogent), T. Lencz, E. Knowles, G. Davies, S. Guha, D. C. Liewald, J. M. Starr, S. Djurovic, I. Melle, K. Sundet, A. Christoforou, I. Reinvang, S. Mukherjee, P. Derosse, A. Lundervold, V. M. Steen, M. John, T. Espeseth, K. Raikkonen, E. Widen, A. Palotie, J. G. Eriksson, I. Giegling, B. Konte, M. Ikeda, P. Roussos, S. Giakoumaki, K. E. Burdick, A. Payton, W. Ollier, M. Horan, G. Donohoe, D. Morris, A. Corvin, M. Gill, N. Pendleton, N. Iwata, A. Darvasi, P. Bitsios, D. Rujescu, J. Lahti, S. L. Hellard, M. C. Keller, O. A. Andreassen, I. J. Deary, D. C. Glahn, Anil Malhotra
Molecular Genetic Evidence For Overlap Between General Cognitive Ability And Risk For Schizophrenia: A Report From The Cognitive Genomics Consortium (Cogent), T. Lencz, E. Knowles, G. Davies, S. Guha, D. C. Liewald, J. M. Starr, S. Djurovic, I. Melle, K. Sundet, A. Christoforou, I. Reinvang, S. Mukherjee, P. Derosse, A. Lundervold, V. M. Steen, M. John, T. Espeseth, K. Raikkonen, E. Widen, A. Palotie, J. G. Eriksson, I. Giegling, B. Konte, M. Ikeda, P. Roussos, S. Giakoumaki, K. E. Burdick, A. Payton, W. Ollier, M. Horan, G. Donohoe, D. Morris, A. Corvin, M. Gill, N. Pendleton, N. Iwata, A. Darvasi, P. Bitsios, D. Rujescu, J. Lahti, S. L. Hellard, M. C. Keller, O. A. Andreassen, I. J. Deary, D. C. Glahn, Anil Malhotra
Journal Articles
It has long been recognized that generalized deficits in cognitive ability represent a core component of schizophrenia (SCZ), evident before full illness onset and independent of medication. The possibility of genetic overlap between risk for SCZ and cognitive phenotypes has been suggested by the presence of cognitive deficits in first-degree relatives of patients with SCZ; however, until recently, molecular genetic approaches to test this overlap have been lacking. Within the last few years, large-scale genome-wide association studies (GWAS) of SCZ have demonstrated that a substantial proportion of the heritability of the disorder is explained by a polygenic component consisting of …
The Relationship Of Neurocognition And Negative Symptoms To Social And Role Functioning Over Time In Individuals At Clinical High Risk In The First Phase Of The North American Prodrome Longitudinal Study, E. C. Meyer, Ricardo Carrion, Barbara Cornblatt, J. Addington, K. S. Cadenhead, T. D. Cannon, T. H. Mcglashan, D. O. Perkins, M. T. Tsuang, L. J. Seidman, +3 Additional Authors
The Relationship Of Neurocognition And Negative Symptoms To Social And Role Functioning Over Time In Individuals At Clinical High Risk In The First Phase Of The North American Prodrome Longitudinal Study, E. C. Meyer, Ricardo Carrion, Barbara Cornblatt, J. Addington, K. S. Cadenhead, T. D. Cannon, T. H. Mcglashan, D. O. Perkins, M. T. Tsuang, L. J. Seidman, +3 Additional Authors
Journal Articles
OBJECTIVES: Impaired social, role, and neurocognitive functioning are preillness characteristics of people who later develop psychosis. In people with schizophrenia, neurocognition and negative symptoms are associated with functional impairment. We examined the relative contributions of neurocognition and symptoms to social and role functioning over time in clinically high-risk (CHR) individuals and determined if negative symptoms mediated the influence of cognition on functioning. METHODS: Social, role, and neurocognitive functioning and positive, negative, and disorganized symptoms were assessed in 167 individuals at CHR for psychosis in the North American Prodrome Longitudinal Study Phase 1 (NAPLS-1), of whom 96 were reassessed at 12 …
The Relationship Between Fasting Serum Glucose And Cerebral Glucose Metabolism In Late-Life Depression And Normal Aging, C. M. Marano, C. I. Workman, C. H. Lyman, E. Kramer, C. R. Hermann, Y. L. Ma, V. Dhawan, T. Chaly, D. Eidelberg, G. S. Smith
The Relationship Between Fasting Serum Glucose And Cerebral Glucose Metabolism In Late-Life Depression And Normal Aging, C. M. Marano, C. I. Workman, C. H. Lyman, E. Kramer, C. R. Hermann, Y. L. Ma, V. Dhawan, T. Chaly, D. Eidelberg, G. S. Smith
Journal Articles
Evidence exists for late-life depression (LLD) as both a prodrome of and risk factor for Alzheimer's disease (AD). The underlying neurobiological mechanisms are poorly understood. Impaired peripheral glucose metabolism may explain the association between depression and AD given the connection between type 2 diabetes mellitus with both depression and AD. Positron emission tomography (PET) measures of cerebral glucose metabolism are sensitive to detecting changes in neural circuitry in LLD and AD. Fasting serum glucose (FSG) in non-diabetic young (YC; n=20) and elderly controls (EC; n=12) and LLD patients (n = 16) was correlated with PET scans of cerebral glucose metabolism …
Excess Of Homozygosity In The Major Histocompatibility Complex In Schizophrenia, S. Mukherjee, S. Guha, M. Ikeda, N. Iwata, Anil Malhotra, I. Pe'er, A. Darvasi, T. Lencz
Excess Of Homozygosity In The Major Histocompatibility Complex In Schizophrenia, S. Mukherjee, S. Guha, M. Ikeda, N. Iwata, Anil Malhotra, I. Pe'er, A. Darvasi, T. Lencz
Journal Articles
Genome-wide association studies (GWAS) in schizophrenia have focused on additive allelic effects to identify disease risk loci. In order to examine potential recessive effects, we applied a novel approach to identify regions of excess homozygosity in an ethnically homogenous cohort: 904 schizophrenia cases and 1640 controls drawn from the Ashkenazi Jewish (AJ) population. Genome-wide examination of runs of homozygosity identified an excess in cases localized to the major histocompatibility complex (MHC). To refine this signal, we used the recently developed GERMLINE algorithm to identify chromosomal segments shared identical-by-descent (IBD) and compared homozygosity at such segments in cases and controls. We …
Matrics Cognitive Consensus Battery (Mccb) Performance In Children, Adolescents, And Young Adults, G. C. Nitzburg, P. Derosse, K. E. Burdick, B. D. Peters, C. B. Gopin, Anil Malhotra
Matrics Cognitive Consensus Battery (Mccb) Performance In Children, Adolescents, And Young Adults, G. C. Nitzburg, P. Derosse, K. E. Burdick, B. D. Peters, C. B. Gopin, Anil Malhotra
Journal Articles
Background: Neurodevelopmental models of schizophrenia suggest that cognitive deficits may be observed during childhood and adolescence, long before the onset of psychotic symptoms. Elucidating the trajectory of normal cognitive development during childhood and adolescence may therefore provide a basis for identifying specific abnormalities related to the development of schizophrenia. The MATRICS Consensus Cognitive Battery (MCCB), which was designed for use in clinical trials targeting cognitive deficits most common in schizophrenia, may provide a mechanism to understand this trajectory. To date, however, there is no performance data for the MCCB in healthy children and adolescents. The present study sought to establish …
Age-Related Differences In White Matter Tract Microstructure Are Associated With Cognitive Performance From Childhood To Adulthood, B. D. Peters, T. Ikuta, P. Derosse, M. John, K. E. Burdick, P. Gruner, D. M. Prendergast, Philip Szeszko, Anil Malhotra
Age-Related Differences In White Matter Tract Microstructure Are Associated With Cognitive Performance From Childhood To Adulthood, B. D. Peters, T. Ikuta, P. Derosse, M. John, K. E. Burdick, P. Gruner, D. M. Prendergast, Philip Szeszko, Anil Malhotra
Journal Articles
Background: Age-related differences in white matter tract microstructure have been well established across the life span. In the present cross-sectional study, we examined whether these differences are associated with neurocognitive performance from childhood to late adulthood. Methods: Diffusion tensor imaging was performed in 296 healthy subjects aged 8 to 68 years (mean = 29.6, SD = 14.6). The corpus callosum, two projection tracts, and five association tracts were traced using probabilistic tractography. A neurocognitive test battery was used to assess speed of processing, attention, spatial working memory, verbal functioning, visual learning, and executive functioning. Linear mediation models were used to …
Delineation Of Hippocampal Subregions Using T1-Weighted Magnetic Resonance Images At 3 Tesla, K. Rhindress, T. Ikuta, R. Wellington, A. K. Malhotra, P. Szeszko
Delineation Of Hippocampal Subregions Using T1-Weighted Magnetic Resonance Images At 3 Tesla, K. Rhindress, T. Ikuta, R. Wellington, A. K. Malhotra, P. Szeszko
Journal Articles
Although several novel approaches for hippocampal subregion delineation have been developed, they need to be applied prospectively and may be limited by long scan times, the use of high field (>3T) imaging systems, and limited reliability metrics. Moreover, the majority of MR imaging data collected to date has employed a T1-weighted acquisition, creating a critical need for an approach that provides reliable hippocampal subregion segmentation using such a contrast. We present a highly reliable approach for the identification of six subregions comprising the hippocampal formation from MR images including the subiculum, dentate gyrus/cornu Ammonis 4 (DG/CA4), entorhinal cortex, fimbria, …
Biological Insights From 108 Schizophrenia-Associated Genetic Loci, S. Ripke, B. M. Neale, A. Corvin, J. T. R. Walters, K. H. Farh, T. Lencz, A. K. Malhotra, Consortium Psychiat Genomics, Conso Psychosis Endophenotypes Int, Consor Wellcome Trust Case-Control, +292 Additional Authors
Biological Insights From 108 Schizophrenia-Associated Genetic Loci, S. Ripke, B. M. Neale, A. Corvin, J. T. R. Walters, K. H. Farh, T. Lencz, A. K. Malhotra, Consortium Psychiat Genomics, Conso Psychosis Endophenotypes Int, Consor Wellcome Trust Case-Control, +292 Additional Authors
Journal Articles
Schizophrenia is a highly heritable disorder. Genetic risk is conferred by a large number of alleles, including common alleles of small effect that might be detected by genome-wide association studies. Here we report a multi-stage schizophrenia genome-wide association study of up to 36,989 cases and 113,075 controls. We identify 128 independent associations spanning 108 conservatively defined loci that meet genome-wide significance, 83 of which have not been previously reported. Associations were enriched among genes expressed in brain, providing biological plausibility for the findings. Many findings have the potential to provide entirely new insights into aetiology, but associations at DRD2 and …
White Matter Changes Associated With Antipsychotic Treatment In First-Episode Psychosis, P. Szeszko, D. G. Robinson, T. Ikuta, B. D. Peters, J. Gallego, J. Kane, A. K. Malhotra
White Matter Changes Associated With Antipsychotic Treatment In First-Episode Psychosis, P. Szeszko, D. G. Robinson, T. Ikuta, B. D. Peters, J. Gallego, J. Kane, A. K. Malhotra
Journal Articles
Second-generation antipsychotics are utilized extensively in the treatment of psychotic disorders and other psychiatric conditions, but the effects of these medications on human brain white matter are not well understood. We thus investigated the effects of second-generation antipsychotics on white matter integrity using tract-based spatial statistics in patients experiencing a first episode of psychosis with little or no prior antipsychotic exposure, and how potential changes were associated with metabolic side effects. Thirty-five (26 men/9 women) patients experiencing a first episode of psychosis received diffusion tensor imaging (DTI) exams, clinical assessments, and provided fasting blood samples at the onset of antipsychotic …
Prevalence And Correlates Of Antipsychotic Polypharmacy In Children And Adolescents Receiving Antipsychotic Treatment*, N. Toteja, J. Gallego, E. Saito, T. Gerhard, A. Winterstein, M. Olfson, C. U. Correll
Prevalence And Correlates Of Antipsychotic Polypharmacy In Children And Adolescents Receiving Antipsychotic Treatment*, N. Toteja, J. Gallego, E. Saito, T. Gerhard, A. Winterstein, M. Olfson, C. U. Correll
Journal Articles
Antipsychotic polypharmacy (APP), which is common in adults with psychotic disorders, is of unproven efficacy and raises safety concerns. Although youth are increasingly prescribed antipsychotics, little is known about APP in this population. We performed a systematic PubMed search (last update 26 January 2013) of studies reporting the prevalence of APP in antipsychotic-treated youth. Summary statistics and statistical tests were calculated at the study level and not weighted by sample size. Fifteen studies (n=58041, range 68-23183) reported on APP in youth [mean age=13.4 +/- 1.7 yr, 67.1 +/- 10.2% male, 77.9 +/- 27.4% treated with second-generation antipsychotics (SGAs)]. Data collected …
Aggression In Schizophrenia And Its Relationship To Neural Circuitry Of Urgency, P. Szeszko
Aggression In Schizophrenia And Its Relationship To Neural Circuitry Of Urgency, P. Szeszko
Journal Articles
No abstract provided.
Functional Development In Clinical High Risk Youth: Prediction Of Schizophrenia Versus Other Psychotic Disorders, S. I. Tarbox, J. Addington, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, D. O. Perkins, L. J. Seidman, M. T. Tsuang, E. F. Walker, S. W. Woods, +2 Additional Authors
Functional Development In Clinical High Risk Youth: Prediction Of Schizophrenia Versus Other Psychotic Disorders, S. I. Tarbox, J. Addington, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, D. O. Perkins, L. J. Seidman, M. T. Tsuang, E. F. Walker, S. W. Woods, +2 Additional Authors
Journal Articles
This study evaluates premorbid social and academic functioning in clinical high-risk individuals as predictors of transition to schizophrenia versus another psychotic disorder. Participants were 54 individuals enrolled in phase one of the North American Prodrome Longitudinal Study who over two and a half years of follow-up met criteria for schizophrenia/schizophreniform disorder (n=28) or another psychotic disorder (n=26). Social and academic functioning in childhood, early adolescence, and late adolescence was assessed at baseline using the Cannon-Spoor Premorbid Adjustment Scale. Social maladjustment in late adolescence predicted significantly higher odds of transition to schizophrenia versus another psychotic disorder independent of childhood and early …
Stress Exposure And Sensitivity In The Clinical High-Risk Syndrome: Initial Findings From The North American Prodrome Longitudinal Study (Napls), H. D. Trotman, C. W. Holtzman, E. F. Walker, J. M. Addington, C. E. Bearden, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, R. K. Heinssen, T. H. Mcglashan, +5 Additional Authors
Stress Exposure And Sensitivity In The Clinical High-Risk Syndrome: Initial Findings From The North American Prodrome Longitudinal Study (Napls), H. D. Trotman, C. W. Holtzman, E. F. Walker, J. M. Addington, C. E. Bearden, K. S. Cadenhead, T. D. Cannon, B. Cornblatt, R. K. Heinssen, T. H. Mcglashan, +5 Additional Authors
Journal Articles
There is inconsistent evidence for increased stress exposure among individuals at clinical high risk (CHR) for psychosis. Yet similar to patients with a diagnosed psychotic illness, the preponderance of evidence suggests that CHR individuals tend to experience stressful life events (LE) and daily hassles (DH) as more subjectively stressful than healthy individuals. The present study utilizes data from the North American Prodrome Longitudinal Study Phase 2 (NAPLS-2) to test the hypotheses that (1) CHR individuals manifest higher self-reported stress in response to both LE and DH when compared to healthy controls (HC), (2) group differences in self-reported stress increase with …
Moderator Effects Of Working Memory On The Stability Of Adhd Symptoms By Dopamine Receptor Gene Polymorphisms During Development, J. Trampush, M. M. Jacobs, Y. L. Hurd, J. H. Newcorn, J. M. Halperin
Moderator Effects Of Working Memory On The Stability Of Adhd Symptoms By Dopamine Receptor Gene Polymorphisms During Development, J. Trampush, M. M. Jacobs, Y. L. Hurd, J. H. Newcorn, J. M. Halperin
Journal Articles
We tested the hypothesis that dopamine D1 and D2 receptor gene (DRD1 and DRD2, respectively) polymorphisms and the development of working memory skills can interact to influence symptom change over 10 years in children with attention-deficit/hyperactivity disorder (ADHD). Specifically, we examined whether improvements in working memory maintenance and manipulation from childhood to early adulthood predicted the reduction of ADHD symptoms as a function of allelic variation in DRD1 and DRD2. Participants were 76 7-11-year-old children with ADHD who were genotyped and prospectively followed for almost 10 years. ADHD symptoms were rated using the Attention Problems scale on the Child Behavior …
Antidepressants For Cognitive Impairment In Schizophrenia - A Systematic Review And Meta-Analysis, J. A. Vernon, E. Grudnikoff, A. J. Seidman, T. W. Frazier, M. S. Vemulapalli, P. Pareek, T. Goldberg, J. Kane, C. U. Correll
Antidepressants For Cognitive Impairment In Schizophrenia - A Systematic Review And Meta-Analysis, J. A. Vernon, E. Grudnikoff, A. J. Seidman, T. W. Frazier, M. S. Vemulapalli, P. Pareek, T. Goldberg, J. Kane, C. U. Correll
Journal Articles
Background: Cognitive impairment in schizophrenia is disabling, but current treatment options remain limited. Objective: To meta-analyze the efficacy and safety of adjunctive antidepressants for cognitive impairment in schizophrenia. Data sources and study selection: PubMed, MEDLINE, PsycINFO, and Cochrane Library databases were searched until 12/2013 for randomized controlled trials comparing antidepressant augmentation of antipsychotics with placebo regarding effects on cognitive functioning in schizophrenia. Data extraction: Two authors independently extracted data. Standardized mean differences (SMDs) were calculated for continuous outcomes and risk ratios for categorical outcomes. SMDs of individual cognitive tests were pooled on a study level within domains (primary outcome) and …
Rdocs Redux, D. R. Weinberger, T. Goldberg
Prospective Memory Performance In Non-Psychotic First-Degree Relatives Of Patients With Schizophrenia: A Controlled Study, F. C. Zhou, W. M. Hou, C. Y. Wang, G. S. Ungvari, H. F. K. Chiu, C. U. Correll, D. H. K. Shum, D. Man, D. T. Liu, Y. T. Xiang
Prospective Memory Performance In Non-Psychotic First-Degree Relatives Of Patients With Schizophrenia: A Controlled Study, F. C. Zhou, W. M. Hou, C. Y. Wang, G. S. Ungvari, H. F. K. Chiu, C. U. Correll, D. H. K. Shum, D. Man, D. T. Liu, Y. T. Xiang
Journal Articles
Objective: We aimed at investigating prospective memory and its socio-demographic and neurocognitive correlates in nonpsychotic, first-degree relatives (FDRs) of patients with schizophrenia compared to patients with first episode schizophrenia (FES), and healthy controls (HCs). Methods: Forty-seven FES patients, 50 non-psychotic FDRs (23 offspring and 27 siblings) of patients with chronic schizophrenia (unrelated to the FES group) and 51 HCs were studied. The Chinese version of the Cambridge Prospective Memory Test (C-CAMPROMPT) was used to measure time-based prospective memory (TBPM) and event-based prospective memory (EBPM) performance. Other cognitive functions (involving respective memory and executive functions) were evaluated with standardized tests. Results: …
Overexpressed Beta-Catenin Localizes To Plasma Membrane In Respiratory Papillomas, A. V. Lucs, A. L. Abramson, B. M. Steinberg
Overexpressed Beta-Catenin Localizes To Plasma Membrane In Respiratory Papillomas, A. V. Lucs, A. L. Abramson, B. M. Steinberg
Journal Articles
No abstract provided.
Early Efficacy Trial Of Anakinra In Corticosteroid-Resistant Autoimmune Inner Ear Disease, A. Vambutas, M. Lesser, V. Mullooly, S. Pathak, G. Zahtz, L. M. Rosen, E. Goldofsky
Early Efficacy Trial Of Anakinra In Corticosteroid-Resistant Autoimmune Inner Ear Disease, A. Vambutas, M. Lesser, V. Mullooly, S. Pathak, G. Zahtz, L. M. Rosen, E. Goldofsky
Journal Articles
BACKGROUND. Autoimmune inner ear disease (AIED) is a rare disease that results in progressive sensorineural hearing loss. Patients with AIED initially respond to corticosteroids; however, many patients become unresponsive to this treatment over time, and there is no effective alternative therapy for these individuals. METHODS. We performed a phase I/II open-label, single-arm clinical trial of the IL-1 receptor antagonist anakinra in corticosteroid-resistant AIED patients. Given that the etiology of corticosteroid resistance is likely heterogeneous, we used a Simon 2-stage design to distinguish between an unacceptable (= 30%) response rate to anakinra therapy. Subjects received 100 mg anakinra by subcutaneous injection …
Circulating Complexes Of The Vitamin D Binding Protein With G-Actin Induce Lung Inflammation By Targeting Endothelial Cells, L. Y. Ge, G. Trujillo, E. J. Miller, R. R. Kew
Circulating Complexes Of The Vitamin D Binding Protein With G-Actin Induce Lung Inflammation By Targeting Endothelial Cells, L. Y. Ge, G. Trujillo, E. J. Miller, R. R. Kew
Journal Articles
This study investigated the actin scavenger function of the vitamin D binding protein (DBP) in vivo using DBP null (-/-) mice. Intravenous injection of G-actin into wild-type (DBP+/+) and DBP-/- mice showed that contrary to expectations, DBP+/+ mice developed more severe acute lung inflammation. Inflammation was restricted to the lung and pathological changes were clearly evident at 1.5 and 4 h post-injection but were largely resolved by 24 h. Histology of DBP+/+ lungs revealed noticeably more vascular leakage, hemorrhage and thickening of the alveolar wall. Flow cytometry analysis of whole lung homogenates showed significantly increased neutrophil infiltration into DBP+/+ mouse …
Bone Morphogenetic Protein-Focused Strategies To Induce Cytotoxicity In Lung Cancer Cells, A. Fotinos, N. Nagarajan, A. S. Martins, D. T. Fritz, D. Garsetti, A. T. Lee, C. C. Hong, M. B. Rogers
Bone Morphogenetic Protein-Focused Strategies To Induce Cytotoxicity In Lung Cancer Cells, A. Fotinos, N. Nagarajan, A. S. Martins, D. T. Fritz, D. Garsetti, A. T. Lee, C. C. Hong, M. B. Rogers
Journal Articles
Background: High bone morphogenetic protein (BMP)-2 expression in lung carcinoma correlates with poor patient prognosis. The present study explored strategies to repress BMP signaling. Materials and Methods: The cytotoxicity of BMP2-knockdown, dorsomorphin derivatives, and microRNAs was tested in transformed and non-transformed lung cells. Microarray analyses of 1,145 microRNAs in A549 lung adenocarcinoma cells and two other transformed lung cell types relative to BEAS-2B bronchial epithelial cells were performed. Results: Reduced BMP2 synthesis inhibited A549 cell growth. The dorsomorphin derivative LDN-193189, but not DMH1 or DMH4, was strongly cytotoxic towards A549 cells, but not towards BEAS-2B cells. Microarray analysis revealed that …